Literature DB >> 23643475

Which regimen is better for stem cell mobilization of lymphoma patients?

Sinem Civriz Bozdağ1, Emre Tekgündüz, Gamze Durgun, Abdurrahman Sarıca, Itır Şirinoğlu Demiriz, Serife Koçubaba, Fevzi Altuntaş.   

Abstract

Although chemotherapy combined with G-CSF is an effective method for hematopoietic stem cell mobilization, standard chemotherapy protocol leading to best stem cell yield is not defined. In our study, we aimed to assess the impact of chemotherapy choice on mobilization outcome in lymphoma patients. Patients were mobilized with cyclophosphamide (n:15), ASHAP (n:11) or VGEPP (n:12) protocols. Groups were similar according to collected CD34+ cell count, total nucleated cell count and median apheresis days. Five out of fifteen (33%) patients could not be mobilized in Cy group but there was only one failed mobilization attempt in both salvage groups (9% with ASHAP vs 8% with VGEPP). In conclusion, we showed that VGEPP and ASHAP are safe protocols in terms of stem cell mobilization and have similar mobilization capacity as cyclophosphamide alone.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23643475     DOI: 10.1016/j.transci.2013.04.027

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  2 in total

1.  Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Authors:  Hikmettullah Batgi; Semih Başcı; Mehmet Sinan Dal; Merih Kızıl Çakar; Bahar Uncu Ulu; Tuğçe Nur Yiğenoğlu; Nurgül Özcan; Ali Kılınç; Alparslan Merdin; Jale Yıldız; Mehmet Bakırtaş; Derya Şahin; Tahir Darçın; Dicle İskender; Nuran Ahü Baysal; Fevzi Altuntaş
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

2.  Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure.

Authors:  Daniëlla W E Roofthooft; Ingrid M van Beynum; Johan C A de Klerk; Monique van Dijk; John N van den Anker; Irwin K M Reiss; Dick Tibboel; Sinno H P Simons
Journal:  Eur J Pediatr       Date:  2015-04-30       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.